Navigation Links
Sequenom Announces Preliminary 2013 Operational Highlights And Objectives For 2014

SAN DIEGO, Jan. 12, 2014 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative testing and genetic analysis solutions, today announced preliminary highlights of the Company's 2013 performance, accomplishments and outlined key corporate objectives for 2014.

Preliminary 2013 Performance Results (unaudited)

  • Total revenue of approximately $162 million, showing growth of approximately 81% year-over-year for 2013
  • Diagnostic services revenues of approximately $120 million, as compared to $46.5 million in 2012.  Diagnostic services revenues continue to be recorded primarily as cash is received
  • High margin stable revenue in the Sequenom Bioscience business of over $42 million
  • Total cash, cash equivalents and marketable securities as of December 31, 2013 were approximately $71 million
  • Cash burn was reduced to approximately $14 million for the fourth quarter of 2013
  • Unrecorded diagnostic accounts receivable are estimated to be $46 to $51 million as of December 31, 2013

Recent Key Accomplishments

  • More than 185,000 total commercial prenatal and retinal diagnostic test samples were accessioned during 2013, as compared to 92,000 in 2012
  • Strong increases  achieved in the adoption rate and sales of Sequenom Laboratories' MaterniT21 PLUS™ laboratory-developed test (LDT):
    • Approximately 148,500 MaterniT21 PLUS test high-risk commercial samples were accessioned in 2013, 140% more than in 2012; 93% of accessions were from U.S. patients
    • MaterniT21 PLUS Enhanced Sequencing Series introduced in Q4 2013
    • Approximately 113 million lives now under coverage with a growing number of payor contracts, including 2 national payors
    • Receiving reimbursement as an out-of-network laboratory from remaining large commercial payors
    • Medicaid volume was reduced to 14% of accessions in Q4 2013 from 25% in Q1 2013; eight state Medicaid payors are now reimbursing
    • Laboratory location in North Carolina fully operational and currently performing approximately one third of MaterniT21 PLUS tests
  • Mayo Clinic and Sequenom Laboratories partnered to provide access to the MaterniT21 PLUS LDT to the physicians and their patients in the Mayo Clinic network  
  • Massively parallel sequencing (MPS) patent issued in Europe, further strengthening Sequenom's prenatal diagnostic patent portfolio

"We overcame many significant challenges in 2013, including the coding changes that resulted in delays or reduced reimbursement by many payors, particularly state Medicaid programs. As we move into 2014, we continue to lead the industry in expanding the use of and reimbursement for noninvasive prenatal testing (NIPT), and continue to work with payors to gain coverage for our tests," said Harry F. Hixson, Jr., Ph.D., Chairman and CEO of Sequenom. "We have set high goals for 2014, and we expect to achieve these goals to continue to build value for our shareholders and maintain our leadership position in NIPT."

Key Objectives for 2014

The Company has established its primary financial and R&D objectives for 2014 to include:

  • Achieve quarterly break-even and positive cash flow in Q4 2014
  • Expand the NIPT menu with the development of a low cost test on an alternative platform by year-end, which we expect will facilitate international access and potential future entry into the low-risk market 

On Thursday, January 16, at 2:00 pm PT (5:00 pm ET), Harry F. Hixson, Jr., Ph.D., William Welch, President and COO, and Paul V. Maier, CFO, will present an overview of and update on the Company at the JP Morgan 32nd Annual Healthcare Conference in San Francisco, CA.

The presentation is expected to last approximately 30 minutes and will be webcast live through the "Investors" section of the Sequenom website at An audio replay will be available for 30 days following the initial presentation webcast. The presentation is currently posted on the Company's website.

This press release contains certain unaudited financial results for the Company's fiscal year and fourth quarter ended December 31, 2013. These unaudited results may change as a result of further review by the Company's management and its independent auditors. The completion of the audit of our financial results for 2013 could result in changes to the unaudited financial results presented in this press release and may identify issues related to the effectiveness of the Company's internal controls over financial reporting.

About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genomic and genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

About Sequenom Laboratories
Sequenom Laboratories, a CAP accredited and CLIA-certified molecular diagnostics laboratory, has developed a broad range of laboratory tests with a focus on prenatal and ophthalmological diseases and conditions. Branded under the names SensiGene™, MaterniT21 PLUS™, HerediT™, NextView™ and RetnaGene™, these molecular genetic laboratory-developed tests provide early patient management information for obstetricians, geneticists, maternal fetal medicine specialists and ophthalmologists. Sequenom Laboratories is changing the landscape in genetic disorder diagnostics using proprietary cutting edge technologies.

SEQUENOM®, MaterniT21™ PLUS, SensiGene™, HerediT™, NextView™, RetnaGene™, IMPACT Dx™ and MassArray® are trademarks of Sequenom, Inc. All other trademarks and service marks are the property of their respective owners.

Forward-Looking Statement
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the Company's objectives for 2014 including primary financial and R&D objectives, expectations of continued reimbursement from large commercial payors, the Company's expectations to continue to lead the industry in expanding the use of and reimbursement for noninvasive prenatal testing (NIPT) and to work with payors to gain coverage for its tests, the Company's goals for 2014 and expectations to achieve those goals to continue to build value for shareholders and maintain its leadership position in NIPT, further review of financial results for the fiscal year and quarter ended December 31, 2013 to be conducted by the Company's management and its independent auditors, the completion of the audit of the Company's financial results for 2013 and its potential change or impact on the unaudited financial results presented herein and/or identification of issues related to the effectiveness of the Company's internal controls over financial reporting, and the Company's commitment to improving healthcare through revolutionary genomic and genetic analysis solutions are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with market demand for and acceptance and use of technology and tests such as the MaterniT21 PLUS test, reliance upon the collaborative efforts of other parties such as, without limitation, healthcare providers, international distributors and licensees, the Company or third parties obtaining or maintaining regulatory approvals that impact the Company's business, government regulation particularly with respect to diagnostic products and laboratory developed tests, publication processes, the performance of designed product enhancements, the Company's ability to develop and commercialize technologies and products, particularly new technologies such as noninvasive prenatal diagnostics, laboratory developed tests, and genetic analysis platforms, the Company's financial position, the Company's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, litigation involving the Company, and other risks detailed from time to time in the Company's most recently filed Quarterly Report on Form 10-Q for the quarter ended September 30, 2013 and its Annual Report on Form 10-K for the year ended December 31, 2012, and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.


SOURCE Sequenom, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sequenom, Inc. Reports Financial Results For The First Quarter Of 2012
2. Sequenom Completes International Distribution Agreements To Expand Access To MaterniT21 PLUS Prenatal Testing Service
3. Sequenom Welcomes Myla Lai-Goldman, M.D., To Board Of Directors
4. Sequenom Announces Exercise In Full Of Over-Allotment Option And Completion Of Offering Of $130 Million Of 5.00% Convertible Senior Notes
5. Sequenom CMMs MaterniT21 PLUS LDT Now Reporting On Gender-Specific Chromosomal Abnormalities
6. Sequenom, Inc. Announces Date Of Fourth Quarter And Full Year 2012 Financial Results And Conference Call
7. Sequenom Announces Participation At The Barclays Global Healthcare Conference
8. Sequenom, Inc. Reports Financial Results For The Fourth Quarter And Full Year Of 2012
9. Morning Research on Sequenom, Peregrine Pharma, Onyx Pharma, and Inovio Pharma
10. Sequenom Announces Participation At The Bank Of America Merrill Lynch Health Care Conference
11. Sequenom, Inc. Reports Financial Results For The First Quarter Of 2013
Post Your Comments:
(Date:10/9/2015)... , Oct. 9, 2015  Xavier University,s Center ... with Konica Minolta Medical Imaging (KMMI) on October 12. ... Thinking to help healthcare providers imagine and develop their ... roadmap that they can customize for their practice. ... is the initial procedure, or study, in medical imaging ...
(Date:10/9/2015)... BETHESDA, Maryland , October 9, 2015 ... Pharmaceuticals Inc. (OTCQB: CNBX) has announced its execution of ... Debt & Liabilities Agreement with Cannabics, Inc. a Delaware Corporation, ... the company. --> --> ... internal restructuring of the Company, whereby the Research and ...
(Date:10/9/2015)... MELVILLE, N.Y. , Oct. 9, 2015 ... the world,s largest provider of health care products and ... today reminded its customers that the Henry Schein Disaster ... who experience operational, logistical or financial issues as a ... Carolina . The toll-free number for all ...
Breaking Medicine Technology:
... be showcased at National Health Service EXPOSAN JOSE, Calif., April ... ), a worldwide leader in medical devices for the minimally ... today announced that the UK NHS National Innovation Centre has ... a select innovative technology that is bringing benefits to National ...
... MITI ), a biopharmaceutical company developing novel, ... autoimmune diseases, today announced the filing of the first ... Nycomed for the anti-GM-CSF antibody MT203. Micromet received a ... Nycomed for the achievement of this milestone.Under a 2007 ...
Cached Medicine Technology:
(Date:10/9/2015)... , ... October 09, 2015 , ... A new health ... Exam Aid, is now available online ( ) – just in time for ... says officially begins in October. However, for many in the U.S., the real start ...
(Date:10/9/2015)... ... October 09, 2015 , ... ... audiologists in The Tennessean's eighth annual Toast of Music City, a reader’s choice ... Nashville residents nominated and cast votes for their favorite businesses in over 200 ...
(Date:10/9/2015)... (PRWEB) , ... October 09, 2015 , ... ... company, has announced the final product specifications for TRACTUS, the world’s first sterile ... in the United States in response to the FDA’s recent Unique Device Identifier ...
(Date:10/9/2015)... Stockton, CA (PRWEB) , ... October 09, 2015 ... ... year anniversary of their “Agents of Change” program, a community improvement initiative that ... The newest charity to benefit from the assistance of Confidence Plus Insurance is ...
(Date:10/9/2015)... ... 09, 2015 , ... Prescription Hope, the fastest growing pharmacy ... to save money on the high cost of their prescription medications through their ... and families can receive their medications delivered direct from over 180 U.S.-based pharmaceutical ...
Breaking Medicine News(10 mins):
... concern over skin cancer many people still disregard the use of ... was noticed that one in three Briton do not protect ... cases of skin cancer are diagnosed in the UK each year, ... will treble in the next 30 years. ,Research ...
... born in the United States -- more than double the ... for at least 21 serious disorders, according to the ... ,Massachusetts has failed to make progress on expanding the newborn ... District of Columbia require screening for the 29 core, treatable, ...
... shockingly thin during her performance at Hiro Ballroom on July ... about her emaciated appearance. ,The former Hole singer ... shake, then apologized to the crowd, saying that she "had ... Ensure shakes for my anorexia. You're going to have to ...
... make her sex scenes look realistic has landed her with ... recently admitted that she got into a painful problem while ... Steve Buscemi. ,The 25-year-old actress suffered head injuries ... ,"We were making out and I whacked my head really ...
... In a new study, UCLA researchers measured the effect of ... the physical symptoms of the disease and created ... may help clinicians guide treatment. The study appears in the ... revealed that to effectively treat hepatitis B patients, clinicians need ...
... overall cost-effectiveness of Medicare benefits have been much-debated, new ... receiving benefits at age 65 required more intensive ... insured prior to receiving Medicare. These findings, from researchers ... 12 issue of the New England Journal of Medicine. ...
Cached Medicine News:
Indications For Usage: ,Adult (recommended tidal volume >150ml), single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to ...
Indications For Usage: ,Adult (recommended tidal volume >150ml), single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to ...
... The Portex® Thermovent® T helps provide protection ... It is small and extremely lightweight making it ... adults. With a high rate of heat and ... secretion retention., ,All HMEs and filters have ...
... helps provide protection to the exposed airway of ... lightweight making it ideal for active young children ... of heat and moisture recovery, it ensures patient ... and filters have ISO standard tapered ends to ...
Medicine Products: